Do Certain Atypical Antipsychotics Increase the Risk of Diabetes? A Critical Review of 17 Pharmacoepidemiologic Studies

References

• Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. I Clin Psychiatry 1997; 58:538–546
   PubMed Web of Science ®Google Scholar
• Csemansky JG, Mahmoud R, Brenner R: A comparison of risperi-done and haloperidol for the prevention of relapse in patients with schizophrenia. NE JM 2002; 346:16–22
   Google Scholar
• McGurk SR, Green MF, Wirshing WC, et al.: The effects of ris-peridone versus haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trail making test. CNS Spectrums 1997; 2:606–604
   Google Scholar
• Mir S, Taylor D: Atypical antipsychotics and hyperglycemia. International Clinical Psychopharmacology 2001; 16:63–74
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Nathan AM, Smith RC: Hyperglycemia associ-ated with the use of atypical antipsychotics. I Clin Psychiatry 2001; 62\(suppl 23):30–38
   Google Scholar
• Liebzeit KA, Markowitz JS, Caley CF: New onset diabetes and atypical antipsychotics. European NeuroPsychopharmacology 2001; 11:25–32
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wishing WC: Novel antipsychotics and new onset diabetes. Biological Psychiatry 1998; 44:778–783
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686–1696
   Google Scholar
• Meyer JM: Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001; 62\(suppl 27):27–34.
   Google Scholar
• Ai D, Roper TA, Riley JA: Diabetic ketoacidosis and clozapine. Postgraduate Medicine 1998; 74:493–494
   Google Scholar
• Bellinger TL, Mendelson DC, Dorson PG, Crismon ML: Olanzapine-induced glucose dysregulation. Annals of Pharmacotherapy 2000; 34:865–867
   Google Scholar
• Bechara CI, Goldman-Levine JD: Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Phar-macotherapy 2001; 21:1444–1447.
   Google Scholar
• Bonanno DG, Davydov L, Botts SR: Olanzapine-induced diabetes mellitus. Annals of Pharmacotherapy 2001; 35:563–565.
   PubMed Web of Science ®Google Scholar
• Fertig MK, Brooks VG, Shelton PS, English CW: Hyperglycemia associated with olanzapine [letter]. J Clin Psychiatry 1998; 59:687–689
   PubMedGoogle Scholar
• Gatta B, Rigalleau V, Gin H: Diabetic ketoacidosis with olanzap-Me treatment [letter]. Diabetes Care 1999; 22:1002–1003
   PubMedGoogle Scholar
• Goldstein LE, Sporn J, Brown S et al.: New-onset diabetes melli-tus and diabetic ketoacidosis associated with olanzapine treat-ment. Psychosomatics 1999; 40:438–443
   PubMed Web of Science ®Google Scholar
• Koller E, Doraiswamy PM: Olanzapine-associated diabetes melli-tus. Pharmacotherapy 2002; 22:841–852
   PubMed Web of Science ®Google Scholar
• Koller EA, Schneider B, Bennett K, Dubitsky G: Clozapine-associated diabetes. American Journal of Medicine 2001; 111:716–723
   PubMed Web of Science ®Google Scholar
• Koren W, Kreis Y, Duchowiczny K, et al.: Lactic acidosis and fatal myocardial failure due to clozapine. Annals of Pharmaco-therapy 1997; 31:168–170
   Google Scholar
• Kostakoglu AE, Yazici KM, Erbas T, Guvener N: Ketoacidosis as a side-effect of clozapine: A case report. Acta Psychiatr Scand 1996; 93:217–218
   PubMedGoogle Scholar
• Koval MS, Rames LJ, Christie S: Diabetic ketoacidosis associated with clozapine treatment [letter]. Am J Psych 1994; 151:1520–1521
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Patel R: Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999; 156:1471.
   PubMed Web of Science ®Google Scholar
• Maule S, Giannella R, Lanzio M, Villari V: Diabetic ketoacidosis with clozapine treatment. Diabetes, Nutrition & Metabolism 1999; 12:187–188
   PubMedGoogle Scholar
• Roefaro J, Mukherjee SM: Olanzapine-induced hyperglycemic nonketonic coma. Annals of Pharmacotherapy 2001; 35:300–302
   PubMed Web of Science ®Google Scholar
• Pierides M: Clozapine monotherapy and ketoacidosis [letter]. Br J Psychiatry 1997; 171:90–91
   PubMed Web of Science ®Google Scholar
• Ragucci KR, Wells BJ: Olanzapine-induced diabetic ketoacidosis. Annals of Pharmacotherapy 2001; 35:1556–1558
   PubMed Web of Science ®Google Scholar
• Smith H, Kenney-Herbert J, Knowles L: Clozapine-induced dia-betic ketoacidosis [letter]. Australian and New Zealand Journal of Psychiatry 1999; 33:120–121
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Gray C, et al.: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five year natural-istic study. Am J Psychiatry 2000; 157:975–981
   Google Scholar
• Metherall R, Younes J: Fatality from olanzapine induced hyperg-lycemia. J Forensic Science 2002; 47:893–896
   Google Scholar
• Rigalleau V, Gatta B, Bonnaud S, et al.: Diabetes as a result of atypical anti-psychotic drugs-a report of three cases. Diabetic Medicine 2000; 17:484–486
   Google Scholar
• Straker D, Mendelowitz A, Karlin L: Near fatal ketoacidosis with olanzapine treatment [letter]. Psychosomatics 2002; 43:339–403
   Google Scholar
• Sobel M, Jaggers ED, Franz MA: New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. J Clin Psychiatry 1999; 160:556–557
   Google Scholar
• Procyshyn RM, Pande S, Tse G: New-onset diabetes mellitus associated with quetiapine [letter]. Canadian J Psychiatry 2000; 45:668–669.
   PubMed Web of Science ®Google Scholar
• Jin H, Meyer JM, Jeste DV: Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associ-ated with atypical antipsychotics: An analysis of 45 published cases. Annals of Clinical Psychiatry 2002; 14:59–64
   PubMedGoogle Scholar
• Croarkin PE, Jacobs KM, Bain BK: Diabetic ketoacidosis associ-ated with risperidone treatment [letter]. Psychosomatics 2000; 41:369–370
   PubMed Web of Science ®Google Scholar
• Haupt DW, Newcomer JW: Risperidone-associated diabetic ketoacidosis [letter]. Psychosomatics 2001; 42:279–280
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC: Risperidone-associated new-onset diabetes. Biological Psychiatry 2001; 50:148–149
   PubMed Web of Science ®Google Scholar
• Kingsbury SJ, Fayek M, Trufasiu D: The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62:347–349
   PubMed Web of Science ®Google Scholar
• Moisan J, Gregoire JP, Gaudet M: Risk of diabetes among risperi-done and olanzapine users. Presented at: Fourth European Con-gress of the International Society for Pharmacoeconomics and Outcomes Research, November 11–13,2001; Cannes, France
   Google Scholar
• Caro JJ, Ward A, Levinton, Robinson K: The risk of diabetes dur-ing olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psych 2002; 63:1135–1139
   Google Scholar
• Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561–566
   PubMed Web of Science ®Google Scholar
• Fuller MA, Shermock KM, Secic M, Grogg A: Comparative study of the development of diabetes mellitus in patients taking risperi-done and olanzapine. Pharmacotherapy 2003; 23:1037–1043
   PubMed Web of Science ®Google Scholar
• Koro CE, Fedder DO, L'Italien GJ, et al.: Assessment of indepen-dent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325:243–245
   Google Scholar
• Gianfrancesco F, Grogg AL, Mahmoud R, Wang RH, Nasrallah HA: Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type II diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63:920–930
   PubMed Web of Science ®Google Scholar
• Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D: Differential effects of antipsychotic agents on the risk of develop-ment of type 2 diabetes mellitus in patients with mood disorders. Clinical Therapeutics 2003a; 25:1150–1171
   PubMed Web of Science ®Google Scholar
• Gianfrancesco F, White RE, Yu E et al.: Antipsychotic-induced type 2 diabetes: Evidence from a large health plan database. J Clin Psychopharmacology 2003b; 23:328–335
   PubMed Web of Science ®Google Scholar
• Lambert, B L., Chou, C-H., Chang, K-Y., Carson W, Tafesse E: Antipsychotic use and new-onset Type II diabetes among schizophrenics [abstract]. Schizophrenia Research 2003; 60\(suppl 1):359
   Google Scholar
• L'Italien GJ, Stump TE, Farwell WR, Wang J, Tafess E, Tierney WM: The effect of olanzapine and risperidone use on new-onset diabetes and weight gain among schizophrenic patients [abstract]. Int J NeuroPsychopharmacology 2002; 5\(suppl 1):5170
   Google Scholar
• Buse JB, Cavazzoni P. Hombuckle K, Hutchings D, Breier A, Jovanovic L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology 2003; 56:164–170
   PubMed Web of Science ®Google Scholar
• Cavazonni P. Hombuckle K, Carlson C, et al.: Diabetes mellitus and antipsychotic treatment in the United Kingdom. Presented at: American College of NeuroPsychopharmacology 40th Annual Meeting; December 9–13,2001; Waikoloa, Hawaii
   Google Scholar
• Feldman PD, Hay LK, Kennedy JS et al.: Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriat-ric population in the United States. Presented at: International College of Geriatric Psychoneuropharmacology; October 10–13, 2002; Barcelona, Spain
   Google Scholar
• Lage MJ, Kemner JE, Hill A: Use of atypical antipsychotics and the incidence of diabetes: Evidence from a claims database [abstract]. Pharmacotherapy 2001; 21:1293
   Google Scholar
• Lee DW, Fowler R, Kadlubek P. Haberman M: No significant dif-ference in the risk of diabetes mellitus during treatment with typi-cal versus atypical antipsychotics: results from a large observational study. Drug Benefit Trends 2002; 14:46–52
   Google Scholar
• Wang PS, Glynn RI, Ganz DA, Schneeweiss S, Levin R, Avorn J: Clozapine use and risk of diabetes mellitus. J Clin Psychophar-macology 2002; 22:236–243
   PubMed Web of Science ®Google Scholar
• Cassidy F, Ahearn E, Carrol BJ: Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psych 1999; 156:1417–1420
   PubMed Web of Science ®Google Scholar
• Grogg A, Markowitz JS, Mahmoud R: Risk of diabetes in Medi-Cal patients prescribed atypical antipsychotics. Presented at: the 6th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, May 1–4,2003; Charleston, S.0
   Google Scholar
• Dixon L, Weiden P. Delahanty J et al.: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bul-letin 2000; 26:903–912
   PubMed Web of Science ®Google Scholar
• Mukherjee W, Decina P. Bocola V. Saraceni F, Scapicchio PL: Diabetes mellitus in schizophrenic patients. Comparative Psychi-atry 1996; 37:68–73
   Google Scholar
• Meltzer HY: Putting metabolic side-effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry 2001; 62\(suppl 27):35–41
   Google Scholar
• Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: Quality of Reporting of Meta-analyses. Lancet 1999; 354:1896–1900
   PubMed Web of Science ®Google Scholar
• McAuley L, Pham B, Tugwell P. Moher D: Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000; 356:1228–1231
   Google Scholar
• Koller EA, Doraiswamy PM, Cross if: Risperidone-associated diabetes. Presented at: 85th annual meeting of the Endocrine Society; June 19–22,2002; Philadelphia, Pennsylvania
   Google Scholar
• Komegay CJ, Vasilakis-Scaramozza C, Jick H: Incident diabetes associated with antipsychotic use in the United Kingdom General Practice Research Database. Journal of Clinical Psychiatry 2002; 63:758–762
   Google Scholar
• Hedenmalm K, Hagg S, Stahl M, Mortimer 0, Spigset 0: Glucose intolerance with atypical antipsychotics. Drug Safety 2002; 25:1107–1116
   PubMed Web of Science ®Google Scholar
• Hosner DW, Lemeshow S: Applied Logistic Regression. New York, NY: John Wiley and Sons, 1989
   Google Scholar
• Haffner SM. Epidemiology of type 2 diabetes: Risk factors. Dia-betes Care 1998; 21\(suppl 3):C3–C6
   Google Scholar
• King H, Rewers M: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16:157–177
   PubMed Web of Science ®Google Scholar
• Kane JM: Pharmacologic treatment of schizophrenia. Biological Psychiatry 1999; 46:1396–1408
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154:1–63
   Web of Science ®Google Scholar
• Simpson JC, Tsuang MT: Mortality among patients with schizo-phrenia. Schizophrenia Bulletin 1996; 22:485–499
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Davidson M, Glassman AH: Assessing cardiovascu-lar risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002; 63\(suppl 9):25–29
   Google Scholar
• Angst F, Stassen HH, Clayton PJ: Mortality of patients with mood disorders: follow-up over 34-38 years. Journal of Affective Disor-ders 2002; 68:167–181
   PubMed Web of Science ®Google Scholar
• Muller-Oerlinghausen B, Berghofer A: Bipolar disorder. Lancet 2002; 359:241–247
   PubMed Web of Science ®Google Scholar
• McElroy SL, Frye MA, Suppes T: Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63:207–213
   PubMed Web of Science ®Google Scholar
• Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999; 60\(suppl 21):10–15.
   Google Scholar
• Casey DE, Carson WH, Saha AR: Switching patients to aripipra-zole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 2003; 166:391–399
   PubMed Web of Science ®Google Scholar
• Ganguli R, Berry S, Gharabawi G: Randomized assessment of strategies for switching patients with suboptimal treatment out-comes from olanzapine to risperidone. Presented at: 41st Annual Meeting of the American College of NeuroPsychopharmacology; December 8–12,2002; San Juan, Puerto Rico
   Google Scholar